Jorge Plutzky

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.

I. Lingvay, K. Brown-Frandsen, Steven E. Kahn, 2023, The New England journal of medicine.

Atherosclerotic plaque rupture: emerging insights and opportunities.

J. Plutzky, Jorge Plutzky, 1999, The American journal of cardiology.

DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases.

L. Tokgözoğlu, Y. Handelsman, P. Jellinger, 2024, Metabolism: clinical and experimental.

Associations between lipoprotein(a), oxidized phospholipids, and extracoronary vascular disease

S. Tsimikas, Hannah Miksenas, Megan Wong, 2024, Journal of lipid research.

Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial

H. Colhoun, Thomas Idorn, K. Brown-Frandsen, 2024, Nature medicine.

Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial

H. Colhoun, I. Lingvay, D. Dicker, 2024, Nature medicine.

Association of Lipoprotein (a) and Standard Modifiable Cardiovascular Risk Factors With Incident Myocardial Infarction: The Mass General Brigham Lp(a) Registry

S. Divakaran, J. Januzzi, Avinainder Singh, 2024, Journal of the American Heart Association.